Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Levels in Patients with Inflammatory Bowel Disease

被引：0
|
作者：
Afif, Waqqas
Loftus, Edward V.
Faubion, William A.
Hanson, Karen A.
Sandborn, William J.
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A147 / A147
页数：1
相关论文
共 50 条
  • [21] Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
    Bor, Renata
    Farkas, Klaudia
    Fabian, Anna
    Balint, Anita
    Milassin, Agnes
    Rutka, Mariann
    Matuz, Maria
    Nagy, Ferenc
    Szepes, Zoltan
    Molnar, Tamas
    PLOS ONE, 2017, 12 (03):
  • [22] Comparison of 4 assay kits for measuring infliximab trough levels and antibodies to infliximab in patients with inflammatory bowel disease
    Perez, I.
    Fernandez, L.
    Sanchez-Ramon, S.
    Alba, C.
    Olivares, D.
    Mendoza, J. L.
    Rey, E.
    Taxonera, C.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S380 - S380
  • [23] Comparison of Four Assay Kits for Measuring Infliximab Trough Levels and Antibodies to Infliximab in Patients With Inflammatory Bowel Disease
    Enciso, Irene Perez
    Paredes, Lidia Fernandez
    Sanchez-Ramon, Silvia
    Mendoza, Juan L.
    Alba, Cristina
    Olivares, David
    Rey, Enrique
    Taxonera, Carlos
    GASTROENTEROLOGY, 2016, 150 (04) : S415 - S415
  • [24] Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease
    Guiotto, Cristina
    Daperno, Marco
    Frigeri, Francesco
    Vizzini, Margherita
    Cerruti, Roberta
    Ercole, Elena
    Cosimato, Maurizio
    Lavagna, Alessandro
    Germano, Laura
    Migliardi, Marco
    Rocca, Rodolfo
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (02) : 138 - 143
  • [25] IMPROVED PREDICTION OF INFLIXIMAB CLEARANCE USING ERYTHROCYTE SEDIMENTATION RATE AND ANTI-INFLIXIMAB ANTIBODY LEVELS IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Xiong, Y.
    Bauman, L.
    Mizuno, T.
    Fukuda, T.
    Dong, M.
    Rosen, M.
    Vinks, A. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S6 - S6
  • [26] Clinical utility of measuring adalimumab trough levels and antibodies to adalimumab in patients with inflammatory bowel diseases
    Ward, M. G.
    Kariyawasam, V. C.
    Mogan, S. B.
    Blaker, P. A.
    Patel, K. P.
    Pantelidou, M.
    Anderson, S.
    Sanderson, J. D.
    Unsworth, N.
    Arkir, Z.
    Irving, P. M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 100 - 101
  • [27] CLINICAL USE OF INFLIXIMAB TROUGH LEVELS DURING MAINTENANCE IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    van Hoeve, Karen
    Hoffman, Ilse
    Dreesen, Erwin
    Ferrante, Marc
    Ann, Gils
    Vermeire, Severine
    GASTROENTEROLOGY, 2018, 154 (06) : S1042 - S1042
  • [28] Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease
    Lopez-Ibanez, Maria
    Marin-Jimenez, Ignacio
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2016, 39 (04): : 265 - 272
  • [29] Infliximab Dosing for Patients With Inflammatory Bowel Disease, Based on Trough Levels
    Lowe, Anson W.
    Moseley, Richard H.
    GASTROENTEROLOGY, 2015, 148 (07) : 1261 - 1261
  • [30] Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
    Pallagi-Kunstar, Eva
    Farkas, Klaudia
    Szepes, Zoltan
    Nagy, Ferenc
    Szucs, Monika
    Kui, Robert
    Gyulai, Rolland
    Balint, Anita
    Wittmann, Tibor
    Molnar, Tamas
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (17) : 5031 - 5035
12345